Antibe Therapeutics   Report issue

For profit Phase 2
Founded: Toronto Canada (2009)

Organization Overview

First Clinical Trial
2014
NCT03220633
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Antibe Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

naproxen (naprosyn) (1 trial)

Otenaproxesul (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Pain (Phase 1)

Osteoarthritis (Phase 2)

Stomach Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2